Late Onset Alzheimer Dementia in Patients with Genotype E3/E4: A Case Report
Keywords:Alzheimer dementia, Neurocognitive function disorders, Amyloid beta, Apolipoprotein E
BACKGROUND: Dementia is one of the leading causes of disability and dependence in elderly worldwide. Epidemiological statistics indicate that data show that at about 60–80%, Alzheimer’s is the most common type of dementia. Alzheimer’s is also the third-most prominent cause of death in elderly.
CASE REPORT: A 72-years-old male patient, complained by the family often forgets about things that have just been done for 3 years ago. According to the family, patient also often discussing the same things repeatedly. Patients tend not to have the initiative to start his daily activities. The family admitted that patient also became often angry and felt suspicious for the last 2 years. From the mini mental state examination showed disturbances in time orientation and recall; from Montreal Cognitive Assessment Ina found disturbances in visuospatial, fluency, abstraction, delayed memory, and time orientation; accompanied by activities of daily living (ADL) and instrumental ADL disorders. Patient also performed a molecular examination of the apolipoprotein E (APOE) genotype and the genotype E3/E4 was detected.
CONCLUSION: The function of the APOE gene, in particular APOE4, is the most emphasized genetic relationship in late onset Alzheimer’s disease. It is proposed that blocking the action of APOE4 can delay or stop Alzheimer’s disease progression.
Plum Analytics Artifact Widget Block
Ong PA, Muis A, Rambe S, Widjojo FS, Laksmidewi AA. Panduan klinik: Diagnosis dan Penatalaksanaan Demensia. Jakarta: Perhimpunan Dokter Spesialis Saraf Indonesia; 2015.
Stewart R. Cardiovascular factors in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1998;65(2):143-7. PMid:20413875
World Health Organization. Dementia. Geneva: World Health Organization; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia. [Last accessed on 2020 Oct 27].
Alzheimer’s Disease International. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer’s Disease International; 2015. Available from: https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. [Last accessed on 2020 Nov 01].
Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: Assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. https://doi.org/10.2147/clep.s37929 PMid:24470773
Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Translational Neurodegeneration 2018;7:1-7. PMid:29423193
Lakhan SE, Chawla J. Alzheimer Disease; 2019. Available from: https://www.emedicine.medscape.com/article/1134817-verview. [Last accessed on 2020 Nov 13].
Kemenkes RI. Menkes: Lansia Yang Sehat, Lansia Yang Jauh Dari Dementia; 2017. Available from: http://www.depkes.go.id/ article/print/16031000003/menkes-lansia-yang-sehat-lansia-yang-jauh-dari-dementia.html. https://doi.org/10.32528/emp. v2i0.1387. [Last accessed on 2020 Nov 18].
Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, et al. Alzheimer’s disease-related dementias summit 2016: National research priorities. Neurology 2017;89(23):2381-91.PMid:29117955
Zhu XC, Tan L, Wang HF, Jiang T, Cao L, Wang C, et al. Rate of early onset Alzheimer’s disease: A systematic review and meta-analysis. Ann Transl Med. 2015;3(3):38. PMid:25815299
Rosenthal SL, Kamboh MI. Late-onset Alzheimer’s disease genes and the potentially implicated pathways. Curr Gen Med Rep. 2014;2(2):85-101. https://doi.org/10.1007/s40142-014-0034-x PMid:24829845
Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer’s disease: A potential path to precision medicine. Pharmacol Ther. 2019;199:173-87. https://doi.org/10.1016/j.pharmthera.2019.03.005 PMid:30877021
Dai MH, Zheng H, Zeng LD, Zhang Y. The genes associated with early-onset Alzheimer’s disease. Oncotarget. 2018;9(19):15132- 43. https://doi.org/10.18632/oncotarget.23738 PMid:29599933
Apostolova LG, Risacher SL, Duran T. Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis. JAMA Neurol. 2018;75(3):328-41. https://doi.org/10.1001/jamaneurol.2017.4198 PMid:29340569
Mahley RW. Central nervous system lipoproteins highlights. Arterioscler Thromb Vasc Biol. 2016;36(7):1305-15. PMid:27174096
Vélez JI, Lopera F, Sepulveda-Falla D, Patel HR, Johar AS, Chuah A. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease. Mol Psychiatry. 2016;21(7):916-24. https://doi.org/10.1038/mp.2015.177 PMid:26619808
Marais AD, Solomon GA, Blom DJ. Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. Crit Rev Clin Lab Sci 2014;51(1):46-62. https://doi.org/10.3109/10408363.2013.870526 PMid:24405372
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501-18. https://doi.org/10.1038/s41582-019-0228-7 PMid:31367008
Safieh M, Korczyn AD, Michaelson DM. ApoE4: An emerging therapeutic target for Alzheimer’s disease. BMC Med. 2019;17(1):64. https://doi.org/10.1186/s12916-019-1299-4 PMid:30890171
How to Cite
Copyright (c) 2021 Anak Agung Ayu Putri Laksmidewi, Chiquita Putri Vania Rau (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.